1. Inhibitory Antibodies

Inhibitory Antibodies

MCE Inhibitory Antibodies are monoclonal antibodies (mAbs) that have been extensively used in the hottest research areas, such as cancer, immunology and infection. These monoclonal antibodies (mAbs) bind monospecifically to certain cells or proteins, thus stimulating the immune system to attack the malignant tumor cells and preventing tumor growth by blocking specific cell receptors. They can inhibit PD-1, PD-L1, EGFR, VEGFR, TNF-alpha or other targets which are unusually active in diseases, such as non-Hodgkin lymphoma, Hemophilia A, renal cell carcinoma, Parkinson's disease and metastatic HER2-positive breast cancer. For example, by binding to VEGF, Bevacizumab prevents VEGF from interacting with its receptors, thereby inhibiting new vessel growth. Lambrolizumab targets the programmed cell death 1 (PD-1) receptor of lymphocytes. By preventing the binding of its ligands (PD-L1 and PD-L2), Lembrolizumab induces an antitumor immune response.

Inhibitory Antibodies (5):

Cat. No. Product Name Purity Concentration
  • HY-P9907
    Trastuzumab 99.30%
    Trastuzumab is a humanized monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab has been clinically used to treat HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer.
  • HY-P9906
    Bevacizumab >99.0%
    Bevacizumab, a humanized monoclonal antibody, specifically binds to all VEGF-A isoforms with high affinity.
  • HY-P9905
    Cetuximab 99.70%
    Cetuximab is a monoclonal antibody that inhibits epidermal growth factor receptor (EGFR), with antitumor activity.
  • HY-108730
    Avelumab
    Avelumab is a fully human IgG1 anti-PD-L1 monoclonal antibody with potential antibody-dependent cell-mediated cytotoxicity.
  • HY-108463
    A-967079
    A-967079 is a selective TRPA1 receptor antagonist with IC50s of 67 nM and 289 nM at human and rat TRPA1 receptors, respectively, and has good penetration into the CNS.